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Abstract
Here are the cases of three female patients who received long-term rituximab treatment for seropositive, erosive and deforming 
rheumatoid arthritis were reported. After rituximab treatment, they presented with recurrent sinusitis and pneumonia, followed by 
the subsequent development of bronchiectasis. A temporal relationship between rituximab treatment and the onset of respiratory 
complications was exposed as a possible pathogenic mechanism.
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Introduction
Rituximab is a  chimeric monoclonal an-
tibody that targets the transmembrane CD20, 
which induces the ablation of mature pre-B and 
B lymphocytes [1]. It was approved by the Food 
and Drug Administration for the treatment of 
non-Hodgkin’s lymphoma (1997), rheumatoid ar-
thritis (RA) (2006), and positive ANCA vasculitis, 
such as microscopic polyangiitis and granulo-
matosis with polyangiitis (2011) [2]. Other indi-
cations for rituximab treatment in autoimmune 
diseases include systemic lupus erythematosus 
and inflammatory myopathies [3, 4]. The most 
relevant adverse events are related to the infusion 
of rituximab, and less frequently, immunological, 
respiratory, renal, cardiac and haematological di-
sorders as well as the increase of neoplasms and 
infections. Pulmonary adverse reactions occur 
in 5.3% of patients undergoing rituximab treat-
ment [5], including interstitial lung disease [6], 
asthma, bronchiolitis obliterans, hypersensitivity 
pneumonitis, and diffuse alveolar haemorrhage 
[7–9]. A case of a 17-year-old patient who was 
receiving 1000 mg of rituximab every 6 months 
for 6 years for optic neuromyelitis was recently 
published; the patient developed rhinosinusitis 
and recurrent pneumonia with the development 
of bronchiectasis in the context of hypogamaglo-
bulinaemia [10].
Case reports
In a cohort of 964 patients with RA treated 
since 2007 at the Fundación Valle del Lili, a refer-
ral care centre in Southwest Colombia, 164 (17%) 
received biological therapy based on the institu-
tional treatment guidelines. Eighty-four patients 
(8.7%) were given rituximab. The average age at the 
onset of the disease was 34 (range: 17–60, SD 15). 
Indications for the initiation of rituximab treat-
ment were failure to respond to anti-TNF in 45 
(53%) patients, failure to respond to methotrex-
ate in 27 (32%) and other reasons in 12 (14%). 
The average number of rituximab cycles was 4. 
Each cycle comprised a 1000 mg initial dose and 
followed with 1000 mg at 2 weeks, indicated for 
9 months. There was a lack of therapeutic effec-
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tiveness in six patients (7%). In addition to the 
de novo development of bronchiectasis, recurrent 
sinusitis and pneumonias were present in three 
(3.5%) subjects.
Case 1
A 76-year-old woman presenting with seropo-
sitive, erosive and deforming RA, which initiated 
at the age of 58, visited our centre with a history 
of chronic obstructive pulmonary disease (COPD) 
secondary to smoking manifesting with a chro-
nic, productive cough. A chest CT from 2013 is 
shown in Figure 1A. She received methotrexate, 
leflunomide, etanercept (2008–2011) and toci-
lizumab (2011–2013) treatment with a notable 
loss of effectiveness. Rituximab was started with 
a good response in 2013. Two months after the 
fourth cycle of rituximab, she presented with 
pansinusitis and multilobar pneumonia, requiring 
hospital treatment with parenteral antibiotics. 
Three months after this episode, she developed 
a lower respiratory infection with residual cough 
and a progressive increase in expectoration. CT 
of the thorax was performed (Fig. 1B), which 
revealed de novo basal cylindrical bronchiecta-
sis. Liver and kidney function tests and serum 
gammaglobulin levels were normal. Because it 
was suspected that rituximab played a role in the 
development of this pulmonary disease, it was 
decided to withdraw rituximab and initiate oral 
steroids and tofacitinib treatment. The patient 
required chronic respiratory therapy to control 
bronchiectasis symptoms.
Case 2
A 63-year-old woman with occupational ex-
posure to volatile solvents, dust and boiler smoke 
underwent treatment for seropositive, erosive and 
deforming RA since the age of 48. She presented 
with additional conditions, including hypothy-
roidism and kidney stones, and denied smoking. 
She presented refractoriness to the treatment of 
RA with conventional medications (prednisolone, 
methotrexate and hydroxychloroquine). Ritux-
imab was started in 2009. After the fifth cycle of 
rituximab, she presented with recurrent high and 
low respiratory infections (three episodes) that 
required hospital treatments. A chest CT scan 
from 2013, which is shown in Figure 1C, revealed 
mild chronic bronchitic changes. Since then, the 
patient has reported productive and progressive 
cough, as well as episodes of dyspnoea associ-
ated with bronchospasm. Chronic inhalers with 
steroids, bronchodilators, respiratory therapy 
and the management of recurrent infections with 
antibiotic therapy were indicated. A more recent 
chest CT scan from 2017 showed cylindrical bron-
chiectasis in both lower lobes (Fig. 1D), and a CT 
scan of the paranasal sinuses suggested chronic 
sinus disease. CBC, liver and kidney functions 
and serum gammaglobulin levels were normal. 
RA is currently being managed with tofacitinib 
and low doses of oral steroids.
Case 3
A 65-year-old woman presented with se-
ropositive, erosive and deforming RA, which 
initiated at the age of 48. She had a history of 
exposure to wood smoke and cigarettes. She was 
treated for several years with prednisolone, meth-
otrexate and chloroquine. In 2006, etanercept 
was indicated for refractory disease. However, 
she developed drug-induced lupus (DIL) with 
glomerulonephritis and cutaneous involvement. 
Subsequently, etanercept was withdrawn, and rit-
uximab was initiated for both DIL and RA control 
[11]. After the sixth cycle of rituximab, she com-
plained of headache, rhinorrhoea, cough of pro-
gressive intensity, expectoration and dyspnoea. 
Pansinusitis and the incipient development 
of bronchiectasis were documented (Fig. 1E). 
She was hospitalised in 2016 because of worsen-
ing symptoms. The chest CT scan on admission 
is shown in Figure 1f. Klebsiella oxytoca was 
isolated from orotracheal secretion. Chronic ven-
tilator support was necessary, and tracheostomy 
was performed. Six weeks after admission, the 
patient died.
Discussion
This study reported the cases of three female 
patients aged > 60 who received rituximab treat-
ment for the control of seropositive RA refractory 
to conventional and biological treatments. They 
were given four, five and six cycles of rituximab, 
respectively (cycles of 1000 mg every 2 weeks 
every 9 months) before presenting with recurrent 
sinusitis and pneumonia and subsequently, bron-
chiectasis. These three patients had a history of 
smoking and/or exposure to environmental con-
taminants. Sinusitis was confirmed via imaging 
studies, in addition to changes in haematological 
tests that are typically indicative of bacterial 
infection and rising acute phase reactants. They 
presented with cough with high volumes of spu-
tum, which lead to the suspicion of the presence 
of bronchiectasis, which was confirmed with 
a chest CT scan. The patients did not show hy-
pogammaglobulinaemia.
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Figure 1. Case 1: A — chest CT from 2013 reported as normal; B — chest CT from 2015 showing cylindrical bronchiectasis in both lung bases. 
Case 2: C — chest CT from 2013 showing nonspecific bronchial changes; D — chest CT from 2017 showing cylindrical bronchiectasis in both 




Bronchiectasis is a condition wherein the 
bronchi and bronchioles dilate as a consequence 
of the damage to their walls [12], which leads to 
a  loss of the mucociliary defence mechanisms 
with consequent colonisation by microorganisms; 
this in turn causes chronic inflammation and 
worsening of the tissues that integrate the bronchi 
and bronchioles [13–18]. Other conditions that 
may coexist in the same patient, such as foreign 
body aspiration, gastro-oesophageal reflux, im-
mune deficiencies, COPD or conditions similar 
to RA, have previously been associated with the 
development of bronchiectasis in adults [19]. 
Rituximab can affect both cellular and humoral 
immunity [20]. Several of these conditions were 
present in the three patients in this report.
Pulmonary reactions related to rituximab 
treatment were reported to have occurred in 5.3% 
of patients in a previous study [5]. Prolonged 
treatment with this drug has been announced 
to be associated with toxicity in the respiratory 
system, which was named by Bitzan et al. [6] as 
‘rituximab (B-cell depleting antibody) associated 
lung injury (RALI)’. These patients were children 
who presented with haematological malignancies, 
configuring a  form of interstitial lung disease 
with reports of lymphocytic infiltrates in their 
histopathological samples.
The temporal relationship between rituxi-
mab treatment and the onset of respiratory com-
plications, such as chronic sinusitis, recurrent 
pneumonia and the subsequent bronchiectasis, in 
these three patients suggests a pathogenic mecha-
nism. Age, the presence of severe RA and chronic 
exposure to air pollutants may be contributing 
factors that predispose patients to this phenome-
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non. Future studies are needed to corroborate this 
relationship and to make more precise, preventive 
or therapeutic recommendations for the use or 
disuse of long-term rituximab treatment for RA.
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